… of more effective G4 CpG ODN-based vaccine adjuvants against infectious diseases. …
because they are abundant in bacterial and viral DNA but rare in vertebrate DNA. (1) These …

… The DNA released in NETs partially mediated the adjuvant … factors contributing simultaneously
in small animals, and the … Thus, monomeric CpG-B oligonucleotides localize to lysosome-…

… for the effective vaccination of animals need to be selected. … formulated with CpG
oligodeoxynucleotide and innatedefense … system for vaccine immunotherapy: an immunological …

… to be admixed with an adjuvant(s); therefore… adjuvants, monophosphoryl lipid A (MPL),
CpG, and Quillaja saponaria Molina fraction 21 (QS-21), alone or in combination (MCQ [MPL/CpG/…

… stranded DNA (ssDNA), we identified Svg3 as a potent cGAS agonist for versatile applications
in combination cancer immunotherapy (… Svg3 was easily synthesized on automated DNA …

… ) agonist CpG oligodeoxynucleotides (CpG ODN) adjuvant directly forming antigen/adjuvant …
× 0.5) and animals were euthanized when the tumor masses reached 1 cm in diameter. The …

… by the approval of IFN-α2 as an adjuvant in 1995 and IL-2 for the … In model animals, they
achieved comparable disease … They linked the antigen and adjuvant (CpG-DNA/peptide) to a …

… (PTO) backbone for vaccine adjuvants and in cancer therapy … agonists are used in
immunotherapeutic applications 21 . As … and discomfort in experimental animals collecting the …

… DNA constitutes a pathogen-associated molecular pattern (PAMP) that is recognized by
the vertebrate … that iSN34 would be a highly effective adjuvant for Th-1-mediated vaccines. …

… unique adjuvant effects of MPL, CpG, and combination adjuvants on … CpG has been tested
as an immunotherapeutic adjuvant in … was shown to enhance CD8 T cell responses to DNA …